Get Level 2

Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE
REMOVE ADS
REMOVE ADS

Latest Share Chat

  2. Share Prices
  3. Glaxosmithkline Share Price
  4. Glaxosmithkline Share Regulatory News
  5. GSK

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Glaxosmithkline Information

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,983.00    -0.50 (-0.03%)
Bid:
1,978.50
Ask:
1,979.50
Spread: 1.00 (0.051%)
Market Cap: £79.45b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

GSK

11 Jul 2022 17:30

RNS Number : 0768S
FTSE Russell
11 July 2022
 

 

 

GSK (UK): Demerger of Haleon (UK)Changes in FTSE UK Index Series

11 July 2022

Further to the FTSE Russell notice released 15 June 2022 and subject to the completion of the demerger of Haleon (UK, non-constituent) from GSK (UK, constituent), please see details of affected indexes and effective dates below:

 

 

Index

Effective FromStart of Trading

FTSE 100 Index

18 July 2022

FTSE 350 Index

18 July 2022

FTSE All-Share Index

18 July 2022

FTSE 350 Higher Yield Index

18 July 2022

Techmark All Share Index

18 July 2022

FTSE UK Dividend + Index

18 July 2022

 

 

 

 

 

 

For further information please contact FTSE Russell Client Services at info@ftserussell.com or call:

Australia

+1800 653 680

Hong Kong

+852 2164 3333

Japan

+81 3 6441 1440

London

+44 (0) 20 7866 1810

New York

+1866 551 0617

 

Alternatively please visit our website at www.ftserussell.com

Terms of Use | Copyright © 2022 FTSE Russell

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FTSQFLFFLDLBBBF
789101112131415
Date   Source Headline
14th Jan 20253:30 pmRNSDirector/PDMR Shareholding
13th Jan 20253:30 pmRNSDirector/PDMR Shareholding
13th Jan 20257:00 amRNSGSK enters agreement to acquire IDRx, Inc.
10th Jan 20257:00 amRNSShingrix fully liquid accepted for US FDA review
7th Jan 20257:00 amRNSGSK ADC gets FDA breakthrough therapy designation
3rd Jan 20257:00 amRNSGSK’s Nucala approved in China for use in CRSwNP
2nd Jan 20253:00 pmRNSTotal Voting Rights
23rd Dec 20243:30 pmRNSDirector/PDMR Shareholding
20th Dec 20249:00 amRNSBlock Listing Application
20th Dec 20247:00 amRNSHeadline results from phase III FIRST trial
16th Dec 20247:11 amRNSJemperli receives US FDA breakthrough designation
16th Dec 20247:05 amRNSEMA grants PRIME Designation for GSK’227
16th Dec 20247:00 amRNSJemperli receives positive CHMP opinion
12th Dec 20243:30 pmRNSDirector/PDMR Shareholding
9th Dec 20246:29 pmRNSOverall survival data presented for Blenrep
9th Dec 20247:05 amRNSBlenrep combination China filing acceptance
9th Dec 20247:00 amRNSNucala COPD submission accepted by US FDA
5th Dec 20247:00 amRNSZhifei China collaboration revised and extended
2nd Dec 20243:30 pmRNSDirector/PDMR Shareholding
2nd Dec 20243:00 pmRNSTotal Voting Rights
27th Nov 20247:00 amRNSGSK liquid meningitis vaccine authorised in EU
25th Nov 20247:00 amRNSBlenrep combinations accepted for US FDA review
22nd Nov 20247:00 amRNSJapan approves first RSV vaccine for adults 50-59
19th Nov 20243:30 pmRNSDirector/PDMR Shareholding
19th Nov 20247:00 amRNSGLISTEN Trial of Linerixibat Meets Endpoint
14th Nov 20247:00 amRNSGSK announces overall survival results for Blenrep
13th Nov 20243:00 pmRNSBlock listing Interim Review
12th Nov 20243:30 pmRNSDirector/PDMR Shareholding
11th Nov 20243:01 pmRNSGSK publishes provisional 2025 dividend dates
1st Nov 20243:00 pmRNSTotal Voting Rights
30th Oct 20242:29 pmRNSDirector/PDMR Shareholding
30th Oct 20247:00 amRNS3rd Quarter Results
24th Oct 20247:00 amRNSNew positive Arexvy data in younger adults at risk
17th Oct 20243:30 pmRNSDirector/PDMR Shareholding
16th Oct 20244:09 pmRNSDirector/PDMR Shareholding
16th Oct 20247:00 amRNSFDA accepts new drug application for gepotidacin
14th Oct 20243:30 pmRNSDirector/PDMR Shareholding
14th Oct 20247:00 amRNSPositive results of ANCHOR trials of depemokimab
11th Oct 20243:33 pmRNSDirector/PDMR Shareholding
10th Oct 20243:30 pmRNSDirector/PDMR Shareholding
9th Oct 20245:48 pmRNSZantac (ranitidine) litigation settlements
8th Oct 202411:45 amRNSPositive efficacy data of Arexvy over 3 seasons
1st Oct 20243:00 pmRNSTotal Voting Rights
24th Sep 20243:30 pmRNSDirector/PDMR Shareholding
24th Sep 20247:00 amRNSPositive EU opinion for GSK liquid Menveo vaccine
18th Sep 20241:20 pmRNSStatement: Zantac (ranitidine) litigation
17th Sep 20247:00 amRNSJapan Filing Acceptance: Blenrep Multiple Myeloma
13th Sep 20247:00 amRNSChina Breakthrough Therapy Designation for Blenrep
12th Sep 20243:30 pmRNSDirector/PDMR Shareholding
12th Sep 20247:00 amRNSPositive mRNA flu vaccine Phase II headline data
789101112131415

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Recently viewed
JCGI
Jp Morg.chin
LSE
-2.40%
BWY
Bellway
LSE
0.60%
LTI
Lindsell Train
LSE
3.25%
DIG
Dunedin Inc.
LSE
-0.67%
SAFE
Safestore
LSE
-0.72%
Trending
MAC
Marechale Cap.
LSE
0.00%
GST
GSTechnologies
LSE
0.00%
ITM
Itm Power
LSE
-0.54%
IMM
Immupharma
LSE
0.54%
LLOY
Lloyds
LSE
-0.77%